Venaxis, Inc. announced it has fulfilled the requirements for CE Marking in Europe for APPY1, the Company's blood-based appendicitis test. Initial commercialization in Europe is planned to commence in the first quarter 2013 in key territories, including the UK, Italy, France, Germany and Benelux countries. The company expected to announce agreements with top EU distributors beginning in the first quarter 2013.
Market Closed -
Other stock markets
|
After market 08:00:00 pm | |||
9.805 USD | +5.32% |
|
9.7 | -1.07% |
Jul. 12 | Top Cryptocurrencies Rise; Bitcoin Stays Above $57,000 Level | MT |
Jul. 12 | Bitfarms Announces Special Shareholder Meeting | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.62% | 2.83B | |
-11.60% | 5.67B | |
+43.70% | 3.69B | |
-25.00% | 2.77B | |
+121.04% | 1.77B | |
+27.14% | 1.53B | |
+7.20% | 1.45B | |
+13.32% | 1.45B | |
-10.65% | 1.03B | |
-7.94% | 909M |
- Stock Market
- Equities
- RIOT Stock
- News Riot Platforms, Inc.
- Venaxis, Inc. Obtains CE Mark for APPY1 Appendicitis Test